Corpus ID: 4987180

Delivering on the value proposition of precision medicine: the view from healthcare payers.

@article{Kogan2018DeliveringOT,
  title={Delivering on the value proposition of precision medicine: the view from healthcare payers.},
  author={J. Kogan and P. Empey and Justin Kanter and D. Keyser and W. Shrank},
  journal={The American journal of managed care},
  year={2018},
  volume={24 4},
  pages={
          177-179
        }
}
A long-held assumption and expectation has been that genomics-based precision medicine will provide clinicians with the tools and therapies they need to consistently deliver the right treatment to the right patient while simultaneously reducing waste and yielding cost savings for health systems. The pace of discovery within the field of precision medicine has been remarkable, yet optimal uptake of new genetic tests and genetically targeted therapies will occur only if payers recognize their… Expand
3 Citations

References

SHOWING 1-7 OF 7 REFERENCES
Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy
Health Insurers Struggle to Manage Number, Cost of Genetic Tests.
Pharmacogenomics to achieve precision medicine.
  • P. Empey
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2016
Cytochrome p-450 polymorphisms and response to clopidogrel.